Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics (Nasdaq: BIOR) has announced it will report its third quarter 2024 financial results and provide a corporate update. The company will host a conference call and webcast on Thursday, November 14, 2024, after market close at 4:30 PM Eastern time. Investors can access the call through domestic (1-877-423-9813) or international (1-201-689-8573) numbers using Conference ID 13749254. A webcast replay will be available on the company's website for 60 days.
Biora Therapeutics (Nasdaq: BIOR) ha annunciato che presenterà i suoi risultati finanziari per il terzo trimestre del 2024 e fornirà un aggiornamento aziendale. L'azienda terrà una conferenza telefonica e una diretta web giovedì 14 novembre 2024, dopo la chiusura del mercato, alle 16:30 ora orientale. Gli investitori possono accedere alla chiamata tramite numeri domestici (1-877-423-9813) o internazionali (1-201-689-8573) utilizzando l'ID conferenza 13749254. Una registrazione web sarà disponibile sul sito web dell'azienda per 60 giorni.
Biora Therapeutics (Nasdaq: BIOR) ha anunciado que informará sobre sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa. La empresa llevará a cabo una llamada de conferencia y una transmisión web el jueves 14 de noviembre de 2024, después del cierre del mercado a las 4:30 PM hora del Este. Los inversores pueden acceder a la llamada a través de números nacionales (1-877-423-9813) o internacionales (1-201-689-8573) utilizando el ID de conferencia 13749254. Una repetición de la transmisión web estará disponible en el sitio web de la empresa durante 60 días.
Biora Therapeutics (Nasdaq: BIOR)는 2024년 3분기 재무 결과를 보고하고 회사 업데이트를 제공할 것이라고 발표했습니다. 회사는 2024년 11월 14일 목요일 시장 마감 후 동부 표준시 기준 오후 4시 30분에 콘퍼런스 콜 및 웹캐스트를 진행합니다. 투자자들은 국내 전화번호(1-877-423-9813) 또는 국제 전화번호(1-201-689-8573)를 통해 콘퍼런스 ID 13749254를 사용하여 전화에 접속할 수 있습니다. 웹캐스트 재생은 회사 웹사이트에서 60일 동안 제공됩니다.
Biora Therapeutics (Nasdaq: BIOR) a annoncé qu'elle communiquera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour sur l'entreprise. La société organisera une conférence téléphonique et un webinaire le jeudi 14 novembre 2024, après la fermeture du marché à 16h30, heure de l'Est. Les investisseurs peuvent accéder à l'appel via les numéros nationaux (1-877-423-9813) ou internationaux (1-201-689-8573) en utilisant l'ID de conférence 13749254. Un replay du webinaire sera disponible sur le site de l'entreprise pendant 60 jours.
Biora Therapeutics (Nasdaq: BIOR) hat angekündigt, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 bekannt geben und ein Unternehmensupdate bereitstellen wird. Das Unternehmen wird am Donnerstag, den 14. November 2024, nach Marktschluss um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten. Investoren können auf den Anruf über die nationalen (1-877-423-9813) oder internationalen (1-201-689-8573) Nummern mit der Konferenz-ID 13749254 zugreifen. Eine Aufzeichnung des Webcasts wird 60 Tage lang auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets.
Conference Call and Webcast Information | ||
Date: | Thursday, November 14, 2024 | |
Time: | 4:30 PM Eastern time / 1:30 PM Pacific time | |
Conference Call: | Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13749254 | |
Live Webcast: | https://investors.bioratherapeutics.com/events-presentations | |
A replay will remain available for 60 days on the company’s website. | ||
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When will Biora Therapeutics (BIOR) report Q3 2024 earnings?
How can I listen to Biora Therapeutics (BIOR) Q3 2024 earnings call?